SS Innovations International (NASDAQ: SSII) is positioning its SSi Mantra robotic surgical platform for broader global adoption, with CEO Dr. Sudhir Srivastava telling The Motley Fool that the company has completed more than 15,000 procedures using its systems, including roughly 750 cardiac surgeries. The disclosure matters because it moves the company beyond the early-adoption phase and into a scale conversation, giving hospital administrators and investors a concrete clinical track record to weigh against established robotic surgery incumbents.
Perhaps the most consequential element of the strategy is telesurgery. Srivastava said more than 200 telesurgeries have been performed on the platform, 27 of them cardiac, as the company explores ways to extend specialist expertise to underserved communities. If telesurgery matures, it could reshape how care is delivered in regions that lack access to specialized surgeons, turning geography from a barrier into a manageable variable. That ambition is central to the growth story detailed in the SS Innovations International (NASDAQ: SSII) interview.
The company is also leaning on differentiated engineering. Srivastava highlighted the SSi Mantra's 4K 3D visualization, surgeon-controlled anatomical imaging, and a modular design that supports up to five robotic arms. Those features matter competitively because they allow the platform to address a wider range of procedures, potentially increasing utilization per installed system and strengthening the case for hospitals to adopt a challenger platform rather than defaulting to entrenched players.
Manufacturing and regulation are the next frontiers. SS Innovations is preparing to expand Indian production capacity through a planned 10-acre facility, with the objective of bringing additional capabilities in-house. Regulatory applications in Europe and the United States are progressing, and management is targeting international expansion through direct sales and opportunities in ambulatory surgery centers. Each of these steps carries execution risk, but together they outline a path from a regional player to a global contender.
Commercial momentum appears to be supporting that narrative. First-half 2026 revenue rose approximately 66% year-over-year to about $25 million, a figure that gives the expansion plan financial credibility. The full interview discussion, including the strategic rationale behind these moves, is available through the interview transcript, and additional coverage can be found in the full article. The original release is also available via www.newmediawire.com.
The implications extend beyond one company's pipeline. By pairing affordability with advanced visualization and telesurgery capabilities, SS Innovations is testing whether robotic surgery can move from elite academic centers into cost-sensitive markets, including India and ambulatory surgery centers in developed economies. Success would broaden patient access and intensify price competition; failure to clear European and U.S. regulators, or to scale manufacturing on schedule, would cap the opportunity. For now, the combination of clinical volume, telesurgery experience, and revenue growth gives the strategy a measurable foundation.
